Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer

DOI: 10.1080/2162402X.2016.1265720

Keywords: BCG, immunotherapy, non-muscle invasive bladder cancer, Ty21a vaccine

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text